DOCSLIB.ORG

B COMMISSION DECISION of 23 February 1999 Adopting a Register

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B COMMISSION DECISION of 23 February 1999 Adopting a Register 1999D0217 — EN — 27.02.2009 — 007.001 — 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents ►B COMMISSION DECISION of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC) (OJ L 84, 27.3.1999, p. 1) Amended by: Official Journal No page date ►M1 Commission Decision 2000/489/EC of 18 July 2000 L 197 53 3.8.2000 ►M2 Commission Decision 2002/113/EC of 23 January 2002 L 49 1 20.2.2002 ►M3 Commission Decision 2004/357/EC of 7 April 2004 L 113 28 20.4.2004 ►M4 Commission Decision 2005/389/EC of 18 May 2005 L 128 73 21.5.2005 ►M5 Commission Decision 2006/252/EC of 27 March 2006 L 91 48 29.3.2006 ►M6 Commission Decision 2008/478/EC of 17 June 2008 L 163 42 24.6.2008 ►M7 Commission Decision 2009/163/EC of 26 February 2009 L 55 41 27.2.2009 1999D0217 — EN — 27.02.2009 — 007.001 — 2 ▼B COMMISSION DECISION of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 laying down a Community procedure for flavouring substances used or intended for use in or on foodstuffs (1) and in particular Article 3(2) thereof; Whereas, in application of Article 3(1) of Regulation (EC) No 2232/96, Member States, within one year of the entry into force of the above- mentioned Regulation, shall notify to the Commission the list of flavouring substances accepted for use in or on foodstuffs marketed on their territory; Whereas, in application of Article 3(2) of the said Regulation, notified flavouring substances, the legal use of which in one Member State must be recognised by the other Member States, shall be entered in a register adopted in accordance with the procedure laid down in Article 7 of the Regulation; Whereas ist is recognized that in certain Member States, some flavouring substances are presently subject to restrictive or prohibitive measures; Whereas it is recognised that such restrictive or prohibitive measures in force at the date of adoption of the current Decision may continue to be applied, pending completion of the evaluation of the substance; Whereas, in any case, where a Member State notes that a flavouring substance contained in the register may constitute a danger to public health, it may invoke the safeguard procedure provided for in Article 3 (3) of Regulation (EC) No 2232/96; Whereas the register forms the basis of the programme for evaluation provided for in Article 4 of the said Regulation which is to be adopted within ten months of the adoption of the register; Whereas the measures provided for in this Decision are in accordance with the opinion of the Standing Committee for Foodstuffs. HAS ADOPTED THIS DECISION: Article 1 The register of flavouring substances annexed to this Decision is hereby adopted. Article 2 This Decision is addressed to the Member States. (1) OJ L 299, 23.11.1996, p. 1. 1999D0217 — EN — 27.02.2009 — 007.001 — 3 ▼M2 Register of flavouring substances notified by the Member States pursuant to Article 3(1) of Regulation (EC) No 2232/96 of the European Parliament and the Council of 28 October 1996 laying down a Community procedure for flavouring substances used or intended for use in or on foodstuffs ▼M7 __________ ▼M2 In part A, CAS (1), Einecs (2), CoE (3) and FEMA (4) numbers are indicated, where available. A number in the column ‘comments’ refers to one of the following remarks: 1. Substance which, apart from its flavouring properties, is used for other purposes on or in foodstuffs, and, therefore, may be subject to additional legal provisions. 2. Substance the use of which is subject to restrictive or prohibitive measures in certain Member States. 3. Substance to be given priority in the evaluation programme laid down in Regulation (EC) No 1565/2000. 4. Substance on which additional information is to be submitted. 5. Name, synonyms, systematic names, CAS, Einecs, CoE or FEMA number might contain inconsistencies. ▼M3 6. Substance which may not be used in and on food, unless lawfully placed on the market in the Member State(s) concerned. ▼M2 A specific question raised concerned the treatment of salts and other derived compounds from a ‘generic’ substance. Certain substances had been notified with a high degree of precision. Other substances are lacking this detailed iden- tification. On a number of acids or bases, no specific guidance is given on the actual covering of their derived salts. It is provisionally presumed, but only for the purpose of this register, that ammonium, sodium, potassium and calcium salts, as well as chlorides, carbonates and sulphates, are covered by the ‘generic’ substance, providing they have flavouring properties. However, final acceptance will depend of the results of the evaluation, which in these cases should verify carefully the accuracy of such assimilation. (1) Chemical Abstracts Service. (2) European Inventory of Existing Chemical Substances. (3) Council of Europe. (4) Flavour and Extract Manufacturers' Association of the US. 1999D0217 — EN — 27.02.2009 — 007.001 — 4 ▼M2 PART A FLAVOURING SUBSTANCES (ordered by FL numbers) ▼M2 Chemic- FL No CAS Name Fema CoE Einecs FL No Synonyms Systematic name Comments al group 01.001 31 138-86-3 Limonene 2633 491 205-341-0 01.001 1,8(9)-p-Menthadiene; p-Mentha-1,8- 5 diene; 1-Methyl-4-isopropenyl-1-cyclo- hexene; Dipentene; Carvene; Cinene; Citrene; 01.002 31 99-87-6 1-Isopropyl-4-methyl- 2356 620 202-796-7 01.002 p-Cymene; Cymene; p-methyl-isopro- benzene pylbenzene; 4-isopropyl-1-methyl- benzene; Cymol; 4-Methyl-1-isopropyl- benzene; 1-Methyl-4-isopropylbenzene 01.003 31 127-91-3 Pin-2(10)-ene 2903 2114 204-872-5 01.003 beta-Pinene 6,6-Dimethyl-2-methyle- nebicyclo[3.1.1]heptane 01.004 31 80-56-8 Pin-2(3)-ene 2902 2113 201-291-9 01.004 alpha-Pinene 2,6,6-Trimethyl-bicyclo [3.1.1]hept-2-ene 01.005 31 586-62-9 Terpinolene 3046 2115 209-578-0 01.005 p-Menth-1,4(8)-diene; 1-Methyl-4- p-Mentha-1,4(8)-diene isopropylidene-1-cyclohexene; 1,4(8)- Terpadiene; 01.006 31 99-83-2 alpha-Phellandrene 2856 2117 202-792-5 01.006 Phellandrene; 2-Methyl-5-isopropyl-1,3- p-Mentha-1,5-diene cyclohexadiene; 4-isopropyl-1-methyl- 1999D0217 1,5-cyclohexadiene 01.007 31 87-44-5 beta-Caryophyllene 2252 2118 201-746-1 01.007 Caryophyllene; 2-Methylene-6,10,10- 4,11,11-Trimethyl-8- trimethylbicyclo-[7,2,0]-undec-5-ene; methylene-bicyclo[7.2.0] undec-4(trans)-ene — EN 01.008 31 123-35-3 Myrcene 2762 2197 204-622-5 01.008 7-Methyl-3-methylene-1,6-octadiene; 7-Methyl-3-methyle- neocta-1,6-diene — 27.02.2009 01.009 31 79-92-5 Camphene 2229 2227 201-234-8 01.009 3,3-Dimethyl-2-methylenenorcamphene; 2,2-Dimethyl-3-methylenenorbornane 01.010 31 1195-32-0 1-Isopropenyl-4-methyl- 3144 2260 214-795-9 01.010 4,alpha-Dimethylstyrene; p-Isopropenyl benzene toluene; 1-Methyl-4-isopropenyl — benzene; 2-p-tolyl propene; 007.001 01.011 31 644-08-6 4-Methyl-1,1′-biphenyl 3186 2292 211-409-0 01.011 p-Methyldiphenyl; p-Methylphenylbenzene; Phenyl-p-tolyl; — p-Phenyl-toluene; 5 ▼M2 Chemic- FL No CAS Name Fema CoE Einecs FL No Synonyms Systematic name Comments al group 01.013 31 92-52-4 Biphenyl 3129 10978 202-163-5 01.013 Diphenyl; Phenylbenzene; 4 01.014 31 90-12-0 1-Methylnaphthalene 3193 11009 201-966-8 01.014 alpha-Methylnaphthalene; 01.015 31 100-42-5 Vinylbenzene 3233 11022 202-851-5 01.015 Styrene; Vinylbenzol; Phenylethene; 2, 3 Phenylethylene; 01.016 31 495-62-5 1,4(8),12-Bisabolatriene 3331 10979 207-805-8 01.016 gamma-Bisabolene; gamma-Bisabolene; 6-Methyl-2-(4-methylcy- 1-Methyl-4-(1,5-dimethyl-1,4-hexa- clohex-3-enylidene)hept- dienyl)-1-cyclohexene; 5-ene 01.017 31 4630-07-3 Valencene 3443 11030 225-047-6 01.017 1,2,3,5,6,7,8a-Octahydro-1,8a-dimethyl- 1,2-Dimethyl-9-isopro- 7-isopropenyl napthalene pylene-bicyclo[4.4.0]dec- 5-ene 01.018 31 13877-91-3 beta-Ocimene 3539 11015 237-641-2 01.018 trans-beta-ocimene; 1,3,6-octatriene, 3,7-Dimethylocta-1,3 1999D0217 3,7-dimethyl-; (trans),6-triene 01.019 31 99-86-5 alpha-Terpinene 3558 11023 202-795-1 01.019 1-Methyl-4-isopropyl-1,3-cyclohex- p-Mentha-1,3-diene adiene — EN 01.020 31 99-85-4 gamma-Terpinene 3559 11025 202-794-6 01.020 1-Methyl-4-isopropyl-1,4-cyclohex- p-Mentha-1,4-diene — adiene; Moslene; Crithmene; 27.02.2009 01.021 31 29350-73-0 delta-Cadinene 10982 249-580-9 01.021 alpha-, beta-, gamma-, epsilon, 2,3,4,7,8,10-hexahydro- delta-Cadiene; 1,6-dimethyl-4-isopropyl- napthalene — 007.001 01.022 31 469-61-4 alpha-Cedrene 10985 207-418-4 01.022 2,6,6,8-Tetramethyl- tricyclo[5.3.1.0(1.5)] — undec-8-ene 6 ▼M2 Chemic- FL No CAS Name Fema CoE Einecs FL No Synonyms Systematic name Comments al group 01.023 31 3691-12-1 1(5),11-Guaiadiene 11003 201-860-1 01.023 1,4-Dimethyl-7-isopropenyl-delta-9,10- 2,8-Dimethyl-5- octahydroazulene; alpha-Guaiene; isopropenyl-bicyclo[5.3.0] dec-1(7)-ene 01.024 31 5208-59-3 beta-Bourbonene 11931 01.024 2-Methyl-8-methylene-5- isopropyl-tricyclo[5.3.0.0 (2.6)]decane ▼M7 _______ ▼M2 01.026 31 88-84-6 1(5),7(11)-Guaiadiene 201-860-1 01.026 beta-Guaiene; (1S-cis)-1,2,3,4,5,6,7,8-
Load more

Recommended publications
  • Safranal, a Saffron Constituent, Attenuates Retinal Degeneration in P23H Rats
    Safranal, a Saffron Constituent, Attenuates Retinal Degeneration in P23H Rats Laura Ferna´ndez-Sa´nchez1., Pedro Lax1., Gema Esquiva1, Jose´ Martı´n-Nieto1, Isabel Pinilla2, Nicola´s Cuenca1* 1 Department of Physiology, Genetics and Microbiology, University of Alicante, Alicante, Spain, 2 Department of Ophthalmology, University Hospital Lozano Blesa, Zaragoza, Spain Abstract Saffron, an extract from Crocus sativus, has been largely used in traditional medicine for its antiapoptotic and anticarcinogenic properties. In this work, we investigate the effects of safranal, a component of saffron stigmas, in attenuating retinal degeneration in the P23H rat model of autosomal dominant retinitis pigmentosa. We demonstrate that administration of safranal to homozygous P23H line-3 rats preserves both photoreceptor morphology and number. Electroretinographic recordings showed higher a- and b-wave amplitudes under both photopic and scotopic conditions in safranal-treated versus non-treated animals. Furthermore, the capillary network in safranal-treated animals was preserved, unlike that found in untreated animals. Our findings indicate that dietary supplementation with safranal slows photoreceptor cell degeneration and ameliorates the loss of retinal function and vascular network disruption in P23H rats. This work also suggests that safranal could be potentially useful to retard retinal degeneration in patients with retinitis pigmentosa. Citation: Ferna´ndez-Sa´nchez L, Lax P, Esquiva G, Martı´n-Nieto J, Pinilla I, et al. (2012) Safranal, a Saffron Constituent, Attenuates Retinal Degeneration in P23H Rats. PLoS ONE 7(8): e43074. doi:10.1371/journal.pone.0043074 Editor: Alfred Lewin, University of Florida, United States of America Received May 3, 2012; Accepted July 16, 2012; Published August 10, 2012 Copyright: ß 2012 Ferna´ndez-Sa´nchez et al.
    [Show full text]
  • Determinación Técnica Analitos LC
    AGROALIMENTARIO 201 8 LISTADO DE DETERMINACIONES Determinación Técnica Analitos LC Butyric Acid, Hexanoic Acid, Octanoic Acid, Decanoic Acid, Undecanoic Acid, Lauric Acid, Tridecanoic Acid, Myristic Acid, Myristoleic Acid, Pentadecanoic Acid, cis-10-pentadecenoic Acid, Palmitic Acid, Palmitoleic Acid, Heptadecanoic Acid, cis-10-Heptadecanoic Acid, Stearic Acid, trans-9-Elaidic Acid, cis-9- Oleic Acid, linolelaidic Acid, linoleic Acid, arachidic Acid, γ-linolenic Acid, eicosenoic Acid, linolenic Acid, Ácidos Grasos GC 0,10 % heneicosanoic Acid, cis-11,14-Eicosadienoic Acid, Behenic Acid, cis-8,11,14-Eicosatrienoic Acid, Erucic Acid, cis-11,14,17-Eicosatrienoic Acid, cis-5,8,11,14-Eicosatetraenoic Acid, Tricosenoic Acid, cis-13,16- Docosadienoic Acid, Lignoceroic Acid, cis-5,8,11,14,17-Eicosapentaenoic Acid, Nervonic Acid, cis- 4,7,10,13,16,19-Docosahexaenoic Acid, cis-4,7,10,13,16,19-Docosahexaenoic Acid Ácidos Grasos cis-trans GC/MS omega3, omega 6 o DHA y omega 9 0,10 % Ác. Acético, Ác. Ascórbico, Ác.Butírico, Ác. Benzoico, Ác. Cítrico, Ác. Fórmico, Ác. Propiónico, Ác. Ácidos Orgánicos HPLC 10 mg/kg Salicílico, Ác. Sórbico, Ác. Shikímico, Ác. Valérico, Ác. Iso-Valérico, Ác. Hexanoico, Ac. Gluconico Ácidos Orgánicos LC/MS/MS Ac. Gluconico 0.05 g/L Acrilamida LC/MS/MS Acrilamida 1 µg/kg Aflatoxinas LC/MS/MS Aflatoxin B1, Aflatoxin B2, Aflatoxin G1, Aflatoxin G2 1 µg/kg Alcoholes GC 1-Butanol, Ethanol, Hexanol, Isobutanol, Isopropanol, Methanol, Propanol 1 mg/kg Aldehídos GC Formaldehyde, Acetaldehyde, Propanal, Butanal, Furfural 0.1 mg/kg
    [Show full text]
  • Putting a Pause on Pelvic Pain: Nutrition and Supplemental Highlights
    PUTTING A PAUSE ON PELVIC PAIN: NUTRITION AND SUPPLEMENTAL HIGHLIGHTS Lise Alschuler, ND NHAND 2020 DISCLOSURES • Has received compensation for occasional industry-sponsored webinars and educational presentations: • 2020: NutraBioceuticals, Gaia • Co-principal for Thrivers, LLC, an educational company that hosts a weekly health and wellness radio show for consumers and which receives industry sponsorship • 2020: Kyowa Hakko, Dr Ohhria Probiotics, Hyatt Life Sciences • Has received research funding: • Pharmavite (2020) 2 TOPICS • Quick overview of chronic pelvic pain pathways relevant to modification by nutrition and dietary supplements. • Gain familiarity with core dietary approaches with evidence of pain modification effects. • Explore the evidence for specific dietary supplements which may modify chronic pelvic pain. 3 PELVIC PAIN: CENTRALIZED PAIN • Chronic pelvic pain (continuous or intermittent pain x 3-6 months) affects 1 in 5 reproductive aged women. • Pelvic pathology does not necessarily correlate with degree of pelvic pain. • Central pain amplification is a component of chronic pelvic pain resulting in generalized heightened pain sensitivity (hyperalgesia) • Begins with persistent peripheral nociception (most commonly from inflammation or lesions) leading to: • Hyperresponsiveness of dorsal horn spinal neurons via N-methyl-D-aspartic (NMDA) receptors - and / or - • Upregulated nociceptive processing within the brain (catastrophizing) • Evidence of pain centralization in women with chronic pelvic pain is high prevalence of co-morbid conditions: • headaches are found in over 50% • IBS, vulvodynia and/or chronic fatigue syndrome are found in 20% As-Sanie E, et al. Obstetrics and Gynecol. 2013;122(5):1047 4 PAIN CENTRALIZATION IS AFFECTED BY MULTIPLE FACTORS • Peripheral tissue injury or lesion leads to increased NGF and inflammatory mediators (ie TNF�) which cause increased sensory nerve growth and sensitization.
    [Show full text]
  • Preliminary Phytochemical Analysis and Antioxidant, Antibacterial
    Available online: www.notulaebotanicae.ro Print ISSN 0255-965X; Electronic 1842-4309 Not Bot Horti Agrobo , 2015, 43(2):343 -348 . DOI:10.15835/nbha43210089 Preliminary Phytochemical Analysis and Antioxidant, Antibacterial Activities of Crocus alatavicus from Kazakhstan Dariya SATYBALDIYEVA 1*, Valentina MURSALIYEVA 2, Izbassar RAKHIMBAYEV 2, Bolatkhan ZAYADAN 1, Ramazan MAMMADOV 3 1Al-Farabi Kazakh National University, Faculty of Biology and Biotechnology, Al-Farabi 71/6, Almaty 050040, Kazakhstan; [email protected] (*corresponding author); [email protected] 2Institute of Plant Biology and Biotechnology, Laboratory of Clonal Propagation, Timiryazev 45, Almaty 050040, Kazakhstan; [email protected] ; [email protected] 3Pamukkale University, Faculty of Science and Letters, Kinikli 20017, Denizli, Turkey; [email protected] Abstract Phytochemical analysis of C. alatavicus revealed the presence of phenols, flavonoids, anthocyanins, carotenoids, amino acids and carbohydrates. The flavonoid, amino acids and carotenoid contents were higher in aerial part (1.50%, 7.49% and 9.78 mg%, respectively) than in bulb (0.43%, 3.88% and 0.91 mg%, respectively). Total phenolic content (TPC), total antioxidant (TAA), 2.2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging and antibacterial activities of water, methanol, ethanol and dichloromethane extracts from aerial part and bulb were tested. TPC ranged from 13.63 to 72.29 mg gallic acid equivalents (GAE)/g extract. The maximum TAA were observed in ethanol (61.34%) and methanol extracts (46.13%) from aerial part with a high TPC (72.29 and 62.37 mgGAE/g extract, respectively). Ethanol extracts from aerial part and bulb had good scavenger of DPPH radicals (65.5% and 54.08%, respectively) with an IC 50 387 and 447 µg/ml.
    [Show full text]
  • Effect of Oral Saffron Capsules on Sleep Quality in Patients with Diabetes at Zabol-Iran, Bali Medical Journal 6(3): 595-600
    ORIGINAL ARTICLE Bali Medical Journal (Bali Med J) 2017, Volume 6, Number 3: 595-600 P-ISSN.2089-1180, E-ISSN.2302-2914 Effect of oral saffron capsules on sleep quality in ORIGINAL ARTICLE patients with diabetes at Zabol-Iran CrossMark Doi: http://dx.doi.org/10.15562/bmj.v6i3.623 Sadegh Dehghanmehr,1 Hossein Shadadi,2* Ali Mansouri,2 Azizollah Arbabisarjou3 Published by DiscoverSys Volume No.: 6 ABSTRACT Introduction: People with diabetes have delayed sleep compared group and a placebo capsule in the control group, for a week, every day to ordinary people and do not have good sleep quality because between hours 12 to 14 am and after taking lunch. After a week, sleep Issue: 3 of impaired glucose level. Saffron effect on insomnia in several quality measured again. studies on animals have checked, and beneficial results for it have Results: After the intervention, the comparison of the mean scores observed. of two groups showed a significant difference (P = 0.001). Also, Methods: This study was a quasi-experimental study aiming comparison of a total mean score of sleep quality in patients before First page No.: 595 to determine the effect of oral saffron capsules on sleep quality and after intervention showed statistically significant difference in in diabetic patients in the city of Zabol in 2016. This study conducted two groups (p = 0.001). on 50 diabetic patients in Zabol city which were qualified for inclusion Conclusion: Results of this study showed that daily administration P-ISSN.2089-1180 criteria for the study. The sleep quality of patients assessed with of saffron oral capsules improves sleep quality in diabetic patients.
    [Show full text]
  • Herbs for Neurology in Restorative Medicine
    Herbs for Neurology in Restorative Medicine Kevin Spelman, PhD, MCPP Health, Education & Research in Botanical Medicine Financial Disclosure •Consultant for Restorative Formulations •I have been a Natural Products and Cannabis Industry Consultant, for GMPs, Regulatory Issues, Pharmacology, Research Initiatives, New Product Development and Formulation •I have financial interests in the Natural Products Industry The Herbs Phytochemistry is Key Botanical Neuro MOAs • Botanical Medicines may alter neurotransmitter binding and uptake, synthesis, and regulation or supporting healthy function of the endocrine system. • Modulation of neuronal communication – Via specific plant metabolites binding to neurotransmitter/neuromodulator receptors – Via alteration of neurotransmitter synthesis, breakdown and function • Stimulating or sedating CNS activity • Regulating and supporting the healthy function of the endocrine system • Providing increased adaptation to exogenous stressors (adaptogenic/tonic effects • Epigenetic alteration, for example, Hypericum perforatum modulates similar genetic expressions to a conventional antidepressant Sarris J, Panossian A. Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011 Dec;21(12):841-60 Neuro MOAs In Botanicals “more sophisticated neuropharmacologic techniques of the future will reveal novel and marvelously subtle pharmacologic activities for herbal medicines that current research methods fail
    [Show full text]
  • Original Article Anti-Allodynia Effect of Safranal on Neuropathic Pain Induced by Spinal Nerve Transection in Rat
    Int J Clin Exp Med 2014;7(12):4990-4996 www.ijcem.com /ISSN:1940-5901/IJCEM0002918 Original Article Anti-allodynia effect of safranal on neuropathic pain induced by spinal nerve transection in rat Ke-Jun Zhu, Ji-Shun Yang Department of Trauma Surgery, The 100th Hospital of PLA, Suzhou 215007, Jiangsu Province, China Received October 1, 2014; Accepted December 8, 2014; Epub December 15, 2014; Published December 30, 2014 Abstract: In this study, we investigated the anti-allodynia effect of safranal, the main volatile constitute of saffron, in spinal nerve transection model of rats. Meanwhile, to elucidate the mechanism, we determined the dynamic expression changes of glial activation markers (GFAP and OX-42) and inflammatory cytokines (TNF-α and IL-1β) in ipsilateral dorsal horn of lumbar enlargement post surgery. Results showed significant increase of these markers along with development of mechanical allodynia. Safranal (0.1 mg/kg, i.p.) attenuated the pain sensitivity and inhib- ited the expression of these markers. The results demonstrate that the antiallodynia effect of safranal after nerve injury might be attributed to its inhibiting effect on glial activation and inflammatory cytokine production in central nervous system. Keywords: Safranal, anti-allodynia, glial activation, pro-inflammatory cytokines, spinal nerve transection Introduction ranal has yet been elucidated. Moreover, no study has been reported to reveal the underly- Safranal (Figure 1) is the main volatile fraction ing mechanism of the antiallodynia mechanism of Crocus sativus L. (commonly known as saf- of safranal under neuropathic pain conditions. fron) [1], which has been widely used for pain relief and other ailments including broncho- It has been suggested that inflammatory and spasm, asthma and cardiovascular diseases in immune mechanisms play key roles in neuro- traditional medicine of Iran, India, Greece and pathic pain [16].
    [Show full text]
  • Safranal Treatment Improves Hyperglycemia, Hyperlipidemia and Oxidative Stress in Streptozotocin-Induced Diabetic Rats
    J Pharm Pharm Sci (www.cspsCanada.org) 16(2) 352 - 362, 2013 Safranal Treatment Improves Hyperglycemia, Hyperlipidemia and Oxidative Stress in Streptozotocin-Induced Diabetic Rats Saeed Samarghandian1, 2, Abasalt Borji1, 2, Mohammad Bagher Delkhosh2, Fariborz Samini3 1Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. 2Health Strategic Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. 3Neurosurgery Department, Faculty of Science, Mashhad University of Medical Sciences, Mashhad, Iran Received, March 8, 2013; Accepted, July 24, 2013; Published, August 2, 2013. ABSTRACT - Purpose. Clinical research has confirmed the efficacy of several plant extracts in the modulation of oxidative stress associated with diabetes mellitus. Findings indicate that safranal has antioxidant properties. The aim of the present study was the evaluation of possible protective effects of safranal against oxidative damage in diabetic rats. Methods. In this study, the rats were divided into the following groups of 8 animals each: control, untreated diabetic, three safranal (0.25, 0.50, 0.75 mg/kg/day)-treated diabetic groups. Diabetes was induced by streptozotocin (STZ) in rats. STZ was injected intraperitoneally at a single dose of 60 mg/kg for diabetes induction. Safranal (intraperitoneal injection) was administered 3 days after STZ administration; these injections were continued to the end of the study (4 weeks). At the end of the 4-week period, blood was drawn for biochemical assays. In order to determine the changes of cellular antioxidant defense systems, antioxidant enzymes including glutathione peroxidase (GSHPx), superoxide dismutase (SOD) and catalase (CAT) activities were measured in serum. Moreover we also measured serum nitric oxide (NO) and serum malondialdehyde (MDA) levels, a marker of lipid peroxidation.
    [Show full text]
  • Crocus Sativus L. Extracts and Its Constituents Crocins and Safranal; Potential Candidates for Schizophrenia Treatment?
    molecules Review Crocus sativus L. Extracts and Its Constituents Crocins and Safranal; Potential Candidates for Schizophrenia Treatment? Nikolaos Pitsikas Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Thessaly, Biopolis, Panepistimiou 3, 415-00 Larissa, Greece; [email protected]; Tel.: +30-2410-685-535 Abstract: Schizophrenia is a chronic mental devastating disease. Current therapy suffers from various limitations including low efficacy and serious side effects. Thus, there is an urgent necessity to develop new antipsychotics with higher efficacy and safety. The dried stigma of the plant Crocus sativus L., (CS) commonly known as saffron, are used in traditional medicine for various purposes. It has been demonstrated that saffron and its bioactive components crocins and safranal exert a beneficial action in different pathologies of the central nervous system such as anxiety, depression, epilepsy and memory problems. Recently, their role as potential antipsychotic agents is under investigation. In the present review, I intended to critically assess advances in research of these molecules for the treatment of schizophrenia, comment on their advantages over currently used neuroleptics as well-remaining challenges. Up to our days, few preclinical studies have been conducted to this end. In spite of it, results are encouraging and strongly corroborate that additional research is mandatory aiming to definitively establish a role for saffron and its bioactive components for the treatment of schizophrenia. Keywords: Crocus sativus L.; crocins; schizophrenia Citation: Pitsikas, N. Crocus sativus L. Extracts and Its Constituents Crocins and Safranal; Potential Candidates for 1. Schizophrenia Schizophrenia Treatment? Molecules Schizophrenia is a serious chronic mental disease that affects up to 1% of the world 2021, 26, 1237.
    [Show full text]
  • The Relaxant Activity of Safranal in Isolated Rat Aortas Is Mediated Predominantly Via an Endothelium-Independent Mechanism - Vasodilatory Mechanism of Safranal
    ISSN 2093-6966 [Print], ISSN 2234-6856 [Online] Journal of Pharmacopuncture 2016;19[4]:329-335 DOI: https://doi.org/10.3831/KPI.2016.19.034 Original article The Relaxant Activity of Safranal in Isolated Rat Aortas is Mediated Predominantly via an Endothelium-Independent Mechanism - Vasodilatory mechanism of safranal - Bibi Marjan Razavi1, Mojtaba Alipoor Amanloo2, Mohsen Imenshahidi3, Hossein Hosseinzadeh3* 1Targeted Drug Delivery Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 2 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 3 Pharmaceutical Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Key Words Results: Safranal induced relaxation in endotheli- um-intact aortic rings precontracted by using PE or aorta ring, indomethacin, L-NAME, saffron, KCl in a concentration-dependent manner, with a vasodilatory effect maximum relaxation of more than 100%. The relaxant activity of safranal was not eliminated by incubating Abstract the aortic rings with L-NAME (EC50 = 0.29 vs. EC50 = 0.43) or with indomethacin (EC50 = 0.29 vs. EC50 = 0.35), Objectives: Safranal is a pharmacologically active com- where EC50 is the half maximal effective concentration. ponent of saffron and is responsible for the unique aro- Also, the vasodilatory activity of safranal was not mod- ma of saffron. The hypotensive effect of safranal has ified by endothelial removal. been shown in previous studies. This study evaluates the mechanism for the vasodilatory effects induced by Conclusion: This study indicated that relaxant activity safranal on isolated rat aortas. of safranal is mediated predominantly through an en- dothelium-independent mechanism.
    [Show full text]
  • Evidence Based Herbal Medicine and Mental Health
    Journal of Medicinal Plants Evidence Based Herbal Medicine and Mental Health Hajiaghaee R (Ph.D.)1, Akhondzadeh S (Ph.D.)2* 1- Pharmacognosy & Pharmaceutics Department of Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran 2- Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran * Corresponding author: Psychiatric Research Center, Roozbeh Hospital, South Kargar Street, Tehran 13337, Iran Tel: +98-21-88281866, Fax: +98-21-55419113 Email: [email protected] Received: 21 Aug. 2012 Accepted: 16 Nov. 2012 Abstract Many cultures have developed folk herbal remedies for various symptoms of mental illness. An evidence base now is being developed for some of these “alternative” herbal remedies. There has been an increase in the number and proportion of clinical trials of complementary medicine, which suggests a trend toward an evidence-based approach. This review presents the scientific information regarding herbal medicine with evidence based approaches for saffron. Keywords: Crocus sativus, Evidence Based Herbal Medicine, Mental health 1 1 Volume 11, No. 43, Summer 2012 Evidence Based Herbal … Introduction and available in hospitals. Nevertheless, many Complementary medicine are interventions people using herbal medicines find the health that are not widely taught in medical schools care alternatives are more congruent with their and are not part of the usual arsenal of own values, beliefs and philosophical treatments and medications recommended and orientations toward health and life. Similarly, prescribed by physicians and available in it seems likely that many people feel that hospitals. Use of Complementary medicine is herbal medicines are empowering by allowing dependent, not on dissatisfaction with them to treat themselves without seeing a conventional medicine as it is most commonly physician.
    [Show full text]
  • Mini Review: SEDATIVE and HYPNOTIC EFFECTS of IRANIAN
    EXCLI Journal 2011;10:192-197 – ISSN 1611-2156 Received: August 31, 2011, accepted: October 03, 2011, published: October 10, 2011 Mini review: SEDATIVE AND HYPNOTIC EFFECTS OF IRANIAN TRADITIONAL MEDICINAL HERBS USED FOR TREATMENT OF INSOMNIA Sasan Andalib1, Ali Vaseghi2, Golnaz Vaseghi3,*, Azadeh Motavallian Naeini3 1 School of Veterinary Medicine, Islamic Azad University of Tabriz, Tabriz, Iran 2 Department of General Sciences, Capilano University, Vancouver, BC, Canada 3 Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran * corresponding author: email: [email protected]; Contact No.: +983117922628; Fax: +983116680011 ABSTRACT For tens of centuries, plants have been highly valued and regularly used as medicine amongst the masses. Insomnia, a loss of sleep, is mostly treated by synthetic sleeping tablets these days. However, questions have been raised about the safety of prolonged use of artificial sedatives due to their deleterious side effects such as physical dependence. In recent years, there has been an increasing propensity to preclude insomnia by herbal medicines throughout the world. Many herbs have a lengthy background in terms of insomnia treatment in Iran. This paper gives an account of previously published research on sedative and hypnotic effects of medicinal herbs used for treatment of insomnia in Iranian traditional medicine. Keywords: Iranian medicinal herbs, Iranian traditional medicine, insomnia, sedative effect, hypnotic effect INTRODUCTION cines. Some insomniacs rely on sleeping tablets such as benzodiazepines and newer Nowadays, insomnia has been a con- nonbenzodiazepines to get rest (Smith and spicuous problem or disease in our restless Tett, 2010; Richey and Krystal, 2011). De- society.
    [Show full text]